Form D · Pharmaceuticals

Reunion Neuroscience, Inc.

Morristown, NJ · CIK 0002007993

Offering snapshot reported Sep 9, 2025 · SEC filing

Reported sold
$120M
Offering amount: $120M
Investors reported
9
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Jan 12, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 9, 2025Amendment$119,850,000No comparison9SEC filing
May 5, 2025Amendment$68,880,305$35,212,123vs May 6, 20249SEC filing
May 6, 2024Amendment$33,668,182$16,818,182vs Jan 25, 20249SEC filing
Jan 25, 2024Initial$16,850,000No comparison6SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
$0
Finders' fees
$0
Form D file number
021-503441

Source: Form D, filed Sep 9, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Alexander Executive
Nathan Bryson Executive
Michael Ehlers Director
Ansbert Gadicke Director
Alon Lazarus Director
Ellen Lubman Director
Gregory Mayes Director, Executive
Briggs Morrison Director
Mark Pollack Executive
Natalie Sacks Director
Edward Smith Executive
Mark Theeuwes Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1 High Street Court
Morristown, NJ, 07960
Phone: 888-880-7386